Pre-exposure prophylaxis for HIV prevention: how to predict success
- 7 December 2011
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 379 (9835) , 2409-2411
- https://doi.org/10.1016/s0140-6736(11)61852-7
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 2011
- Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative MenThe Journal of Infectious Diseases, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Real-Time Adherence Monitoring for HIV Antiretroviral TherapyAIDS and Behavior, 2010
- High Multiplicity Infection by HIV-1 in Men Who Have Sex with MenPLoS Pathogens, 2010
- HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV preventionInternational Journal of Epidemiology, 2010
- Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Practical and Conceptual Challenges in Measuring Antiretroviral AdherenceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- A Practical Method to Calibrate Self-Reported Adherence to Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006